Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

173.40 +3.49 (+2.05%)
Streaming Delayed Price Updated: 11:44 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
56 57 Next >
News headline image
Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting' ↗
 
Via Benzinga
News headline image
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings ↗
Analysts expect Biogen to report a a decline in both profits and sales in Q2. 
Via Investor's Business Daily
News headline image
Better Big Biotech Buy: Vertex vs. Biogen ↗
These companies have a track record of billion-dollar earnings. 
Via The Motley Fool
News headline image
Biogen Earnings Preview ↗
 
Via Benzinga
News headline image
Biogen Unusual Options Activity ↗
 
Via Benzinga
News headline image
Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc. 
Via Benzinga
News headline image
(BIIB) - Analyzing Biogen's Short Interest ↗
 
Via Benzinga
News headline image
Is Biogen Stock a Buy Now? ↗
The biotech hasn't been the best investment recently. 
Via The Motley Fool
News headline image
Should You Buy the Dip With Biogen Stock Right Now? ↗
It's expected to grow, but things might not work out precisely as planned. 
Via The Motley Fool
News headline image
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
From Biogen Inc.
Via GlobeNewswire
News headline image
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price? 
Via MarketBeat
Topics Initial Public Offering
News headline image
These 2 Numbers Should Scare Every Biogen Shareholder ↗
There are a couple of pieces of evidence that Biogen's long-term strategy isn't working. 
Via The Motley Fool
News headline image
7 Stocks That AI Says Will Make You a Millionaire by 2025 ↗
These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio. 
Via InvestorPlace
News headline image
P/E Ratio Insights for Biogen ↗
 
Via Benzinga
News headline image
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising? ↗
Biogen shares are little changed year to date. 
Via The Motley Fool
News headline image
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today ↗
 
Via Benzinga
News headline image
What 29 Analyst Ratings Have To Say About Biogen ↗
 
Via Benzinga
News headline image
Why Isn't Biogen Stock Soaring After This Major FDA Approval? ↗
Is the stock a good contrarian buy? 
Via The Motley Fool
News headline image
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout. 
Via MarketBeat
News headline image
Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets ↗
 
Via Benzinga
News headline image
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts ↗
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and... 
Via Benzinga
News headline image
What's Going On With Biogen Stock Thursday ↗
Biogen Inc (NASDAQ: BIIB) shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during  
Via Benzinga
News headline image
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline ↗
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. 
Via Benzinga
News headline image
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review ↗
Automakers rallied on sales while Meta's Threads had a big launch. 
Via Investor's Business Daily
News headline image
FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today ↗
First Solar (FSLR) stock is rising higher on Friday after the solar energy company announced a $1 billion revolving credit facility. 
Via InvestorPlace
News headline image
Why Is Alibaba (BABA) Stock Up Today? ↗
Alibaba (BABA) stock is on the rise Friday as investors react to a few pieces of news considering the Chinese e-commerce giant. 
Via InvestorPlace
News headline image
BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug ↗
Biogen (BIIB) stock is in the news Friday after the pharmaceutical company got approval from the FDA for its Alzheimer's drug. 
Via InvestorPlace
News headline image
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move ↗
 
Via Benzinga
News headline image
Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval ↗
 
Via Benzinga
News headline image
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.